Streetbeat News

Price Targets

MIRM

Over the past 3 months, 11 Wall Street analysts have provided ratings for Mirum Pharmaceuticals (NASDAQ:MIRM), with an average price target of $60.82, which is significantly higher than the current price of $32.32. The consensus among these analysts is positive, with 3 bullish and 8 somewhat bullish ratings. However, the current average price target has decreased by 17.25% from the previous target of $73.50.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 3:00 pm

CRNX

Crinetics Pharmaceuticals (NASDAQ:CRNX) received 8 analyst ratings in the last quarter, with an average price target of $41.25, representing an upside from the current price of $30.01. The ratings include 2 bullish and 6 somewhat bullish, with no indifferent, somewhat bearish, or bearish ratings. The new average price target is a 6.25% decrease from the previous target of $44.00. Analysts use various methods to rate stocks, and their predictions can influence trading decisions.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 3:00 pm

DNUT

Krispy Kreme (NASDAQ:DNUT) has received analyst ratings over the last quarter with 1 bullish and 3 indifferent ratings. The average price target is $15.12, which is higher than the current price of $12.82, suggesting an upside. However, this target is a 20.42% decrease from the previous target of $19.00. Analysts typically review stocks quarterly and provide ratings based on company performance and market conditions.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 3:00 pm

PXD

Stifel analyst Derrick Whitfield has maintained a Hold rating on Pioneer Natural Resources (NYSE:PXD) but has reduced the price target from $258 to $243.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 2:59 pm

TSVT

Wedbush analyst David Nierengarten downgraded 2seventy bio (NASDAQ:TSVT) from Outperform to Neutral and set a price target of $2. The downgrade reflects a more cautious stance on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 2:58 pm

RRC

Stifel analyst Derrick Whitfield has maintained a Buy rating on Range Resources (NYSE:RRC) but has lowered the price target from $39 to $38.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 2:56 pm

TALO

Stifel analyst Nate Pendleton has maintained a Buy rating on Talos Energy (NYSE:TALO) but has reduced the price target from $23 to $20.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 2:53 pm

NSTG

TD Cowen analyst Dan Brennan downgraded NanoString Technologies (NSTG) from Outperform to Market Perform and reduced the price target from $6 to $1.4, indicating a more cautious view on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 2:48 pm

TXO

Stifel analyst Derrick Whitfield has maintained a Buy rating on TXO Partners (NYSE:TXO) but has reduced the price target from $28 to $27.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 2:47 pm

PENN

B of A Securities analyst Shaun Kelley has upgraded PENN Entertainment from Neutral to Buy and increased the price target from $27 to $30.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 2:41 pm